Dihydronicotinamid-adenin-dinucleotid

Nadh

HCID 439153CAS 58-68-4

Grundinformationen

Standard-SMILES
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1
InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N
Summenformel
C21H29N7O14P2
Durchschnittliche Molmasse
665,4 g/mol
Monoisotopische Masse
665,12477262

Namen und Bezeichner

Bevorzugter Name
Nadh
IUPAC
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
Lokaler Name
Dihydronicotinamid-adenin-dinucleotid
Englischer Name
dihydrodiphosphopyridine nucleotide
Summenformel
C21H29N7O14P2
Molmasse
665.44

Namen und Synonyme

NADHDPNHbeta-NADH58-68-41,4-Dihydronicotinamide adenine dinucleotideNADH2dihydronicotinamide adenine dinucleotideReduced nicotinamide adenine diphosphateReduced nicotinamide-adenine dinucleotideReduced Nicotinamide Adenine Dinucleotide[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate4J24DQ0916
Weitere Namen anzeigen
NICOTINAMIDE ADENINE DINUCLEOTIDEdihydrocozymaseReduced formβ-NADH, DPNH, NADHReduced codehydrase ITestosterone 17β-dehydrogenase
Nicotinamide-adenine dinucleotide, reducednicotinamide adenine dinucleotide (reduced)CHEBI:16908DTXSID30889320[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acidAdenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamideNAD reduced(((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methoxy)(hydroxy)phosphoryl)oxy)((((2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy))phosphinic acid

Datenbank-Bezeichner

CAS
58-68-4、606-68-8
PubChem CID
439153
DTXSID
DTXSID30889320
ChEMBL
CHEMBL1234616
ChEBI
CHEBI:16908
UNII
4J24DQ0916
EC Number
200-393-0
Nikkaji
J213.546I

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-5,7
Polarare Oberfläche (TPSA)
318 Ų
H-Brücken-Donoren
8
H-Brücken-Akzeptoren
19
Frei drehbare Bindungen
11
Schwere Atome
44

Experimentelle und physikochemische Eigenschaften

LogP-5.1
Melting Point · 2 Einträge

140.0-142.0 °C

140.0 - 142.0 °C

Physical DescriptionSolid

Physikochemische Eigenschaften

Siedepunkt
1081.8 · 1081.8±75.0 °C(Predicted)
Dichte
2.18 · 2.18±0.1 g/cm3(Predicted)
Löslichkeit
Water (Slightly)
pka
1.13 · 1.13±0.50(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White

Sicherheit und Regulatorisches

Gefahrenhinweise

Regulatory Information · 2 Einträge

Chemical: Adenosine 5′-(trihydrogen diphosphate), P′.fwdarw.5′-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide

Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationEvaluation - Chemicals that are unlikely to require further regulation to manage risks to environment

Regulatorische Informationen

Regulatory Information · 2 Einträge

Chemical: Adenosine 5′-(trihydrogen diphosphate), P′.fwdarw.5′-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide

Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard

Sicherheitsdaten

tsca
TSCA listed

Chemie und Industrie

Pharmakologische Informationen

Pharmacodynamics · 1 Eintrag

A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.

Mechanism of Action · 1 Eintrag

NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

Absorption, Distribution and ExcretionUnclear how much of an administered dose is absorbed.
Tissue LocationsBladder;Brain;Fibroblasts;Platelet;Skeletal Muscle
Cellular LocationsEndoplasmic reticulum;Mitochondria;Peroxisome
Metabolite Pathways · 1 Eintrag

11-beta-hydroxylase deficiency (CYP11B1);17-alpha-hydroxylase deficiency (CYP17);17-Beta Hydroxysteroid Dehydrogenase III Deficiency;2-aminoadipic 2-oxoadipic aciduria;2-Hydroxyglutric Aciduria (D And L Form);2-ketoglutarate dehydrogenase complex deficiency;2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);27-Hydroxylase Deficiency;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;Total 46220 pathways, visit the HMDB page for details

Verwendung und Herstellung

General Manufacturing InformationAdenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide: INACTIVE

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Anbieter24 Anbieter

weifang runzhong fine chemical co., ltd536-7868377 +8618653686003 · [email protected]
曼顿生物科技(深圳)有限公司+86-75589664337 +86-15112661142 · [email protected]
湖南瑞威尔生物科技有限公司15608648206 13297919155 · [email protected]
北京博奥森生物技术有限公司400-901-9800 18611424007 · [email protected]
上海梅凯科技有限公司021-68689288 15300790979 · [email protected]

Ergänzende Hinweise

DefinitionChEBI: A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.

Zugehörige Reaktionen

141

Verknüpfte Notizen

Wird geladen…